• FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies

    Share Now3sharesFacebook3Twitter0Google+Pinterest0FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic [..]

  • FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease

    Share Now24sharesFacebook24Twitter0Google+Pinterest0FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease By: Alnylam News Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the [..]

  • WBF NYC 2018 – Nov. 14-15 | NY’s Top Innovation Conference

    Share Now2sharesFacebook2Twitter0Google+Pinterest0WBF NYC 2018 – Nov. 14-15 | NY’s Top Innovation Conference  What is the World Business Forum                                     Organized and curated by WOBI each year in cities across the Americas, Europe and Asia, World Business [..]

  • These On-chip Optical Filter Can Processes Wide Range of Light Wavelengths

    Share Now1sharesFacebook1Twitter0Google+Pinterest0These On-chip Optical Filter Can Processes Wide Range of Light Wavelengths By: Rob Matheson’ | MIT News Office MIT researchers have designed an optical filter on a chip that can process optical signals from across an extremely wide spectrum of light at once, something never before available to integrated [..]

  • New Era for Migraine Patients: EU Approved Aimovig® of Novartis

    Share Now2sharesFacebook2Twitter0Google+Pinterest0New Era for Migraine Patients: EU Approved Aimovig® of Novartis   Novartis announced that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be [..]

  • EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana

    Share Now13sharesFacebook13Twitter0Google+Pinterest0EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug [..]

  • FDA Approves TPOXX® :The First Drug For Smallpox

    Share Now1sharesFacebook1Twitter0Google+Pinterest0FDA Approves TPOXX® :The First Drug For Smallpox SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a [..]

  • Let it rain! New coatings make natural fabrics waterproof

    Share Now1sharesFacebook1Twitter0Google+Pinterest0Let it rain! New coatings make natural fabrics waterproof MIT-developed process could offer nontoxic alternative to environmentally harmful chemicals. By: David L. Chandler | MIT News Office Fabrics that resist water are essential for everything from rainwear to military tents, but conventional water-repellent coatings have been shown to persist [..]

  • This Wireless System Can Power Devices Inside the Body

    Share Now0sharesFacebook0Twitter0Google+Pinterest0This Wireless System Can Power Devices Inside the Body By: Anne Trafton | MIT News Office  MIT researchers, working with scientists from Brigham and Women’s Hospital, have developed a new way to power and communicate with devices implanted deep within the human body. Such devices could be used to [..]

  • Novartis’s Gilenya® got Approved by FDA for Pediatric Relapsing Multiple Sclerosis

    Share Now4sharesFacebook4Twitter0Google+Pinterest0Novartis’s Gilenya® got Approved by FDA for Pediatric Relapsing Multiple Sclerosis By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), [..]

  • FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq

    Share Now3sharesFacebook3Twitter0Google+Pinterest0FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in [..]

shares